Clinical Trial Update: CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001) [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for CD123/CLL1 CAR-T cells in relapsed/refractory acute myeloid leukemia (AML) in Phase 2/Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD123/CLL1 CAR-T cells (CD123/CLL1 CAR-T cells)

Snippet

Sponsor: Fujian Medical University | Conditions: Relapsed/Refractory AML | Phase 2, Phase 3 | Status: UNKNOWN